CD19/CD22 dual-targeting Chimeric antigen receptor T cell therapy bridging to allogeneic hematopoietic stem cell transplantation for B-cell acute lymphoblastic leukemia delays platelet recovery and increases risks of cytomegalovirus and Epstein-Barr Virus viremia after transplantation
Research Square (Research Square)